Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD; NSC# 712227) or in Combination With Weekly Pactilaxel (NSC #673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01294293 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT01294293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01294293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD; NSC# 712227) or in Combination With Weekly Pactilaxel (NSC #673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2011
Completion date
Not reported
Enrollment
20 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

malignant ovarian mixed epithelial tumor, ovarian brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian mucinous cystadenocarcinoma, ovarian serous cystadenocarcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, undifferentiated ovarian carcinoma